secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001437749-23-007529
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Therapeutics reports FY2022 net loss of $26.96M; provides clinical updates on (Z)-endoxifen trials
--------------------------------------------------------------------------------

- Net loss of $26.96M ($0.21 diluted EPS) vs $20.6M loss in FY2021; operating expenses up 35% to $27.7M.
- R&D expenses rose 64% to $15.1M, driven by clinical trials for (Z)-endoxifen and AT-H201 programs.
- Cash, cash equivalents and restricted cash totaled $111M as of Dec 31, 2022, down from $136.5M a year earlier.
- Initiated Phase 2 EVANGELINE study for (Z)-endoxifen in ER+/HER2- breast cancer; first patient dosed.
- Invested $4.7M in Dynamic Cell Therapies, acquiring ~19% stake; new patent granted for enteric capsule formulation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923007529/0001437749-23-007529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923007529/atos20230315_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-007529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer